Life sciences is one of the most heavily regulated industries in Canada, and with this regulatory environment come administrative and constitutional challenges. But what strategies and practical guidance should life sciences companies consider when navigating a changing regulatory environment? What can we learn about public law and the scope of agency oversight over life sciences companies?
Partners Teresa Reguly, Yael Bienenstock and Andrew Bernstein give us a sneak peek into the issues at play in their upcoming webinar on September 24 on public law for life sciences companies, including:
- determining the scope of an agency's oversight and whether they are acting within its authority;
- public law issues that can arise if an agency updates or creates a policy; and
- challenging the designation of a biosimilar as interchangeable.
Register for the upcoming webinar here and play the teaser video below for a preview of what is sure to be an engaging discussion.
self
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
